ArticleCancer biology & medicine2016
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.
Article in Cancer biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies.Hematological oncology · 2018Trial
- Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies.International journal of hematology · 2018Trial
- Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia.Cancer research communications · 2026Article
- A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.Nature communications · 2024Article
- Article
- Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series.Diagnostics (Basel, Switzerland) · 2021Article
- Clinical Proteomics of Biofluids in Haematological Malignancies.International journal of molecular sciences · 2021Review
- Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.International journal of molecular sciences · 2021Review
- Liquid biopsy in NSCLC: a new challenge in radiation therapy.Exploration of targeted anti-tumor therapy · 2021Review
- Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective.World journal of stem cells · 2020Review
- The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant RecipientsBalkan medical journal · 2020Article
- Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.European journal of haematology · 2020Article
- Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics.NPJ precision oncology · 2020Review
- Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.Journal of translational medicine · 2019Article
- Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.Pediatric blood & cancer · 2019Review
- Liquid biopsies in myeloid malignancies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- MiR-145: a potential biomarker of cancer migration and invasion.American journal of translational research · 2019Review
- Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies.Research and reports in urology · 2019Review
- Minimal residual disease analysis in myeloma - when, why and where.Leukemia & lymphoma · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating free nucleic acids; cell free DNA and circulating micro-RNA, are found in the plasma of patients with hematologic and solid malignancies at levels higher than that of healthy individuals. In patients with hematologic malignancy cell free DNA reflects the underlying tumor mutational profile, whilst micro-RNAs reflect genetic interference mechanisms within a tumor and potentially the surrounding microenvironment and immune effector cells. These circulating nucleic acids offer a potentially simple, non-invasive, repeatable analysis that can aid in diagnosis, prognosis and therapeutic decisions in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.